Stuart H Ralston

List of Publications by Year
in descending order

174	13,117	23567	24982
papers	citations	58 h-index	109 g-index

186	186	186	15837
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review. Acta Ophthalmologica, 2022, 100, .	1.1	18
2	Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 2022, 17, 23.	2.7	19
3	Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 2022, 17, 12.	2.4	5
4	Communicating Absolute Fracture Risk Reduction and the Acceptance of Treatment for Osteoporosis. Calcified Tissue International, 2022, 110, 698-702.	3.1	6
5	The Paget's disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	6
6	Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis. Calcified Tissue International, 2022, 110, 273-284.	3.1	22
7	Unusual Causes of Osteoporosis. Calcified Tissue International, 2022, 110, 529-530.	3.1	0
8	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. Scandinavian Journal of Rheumatology, 2022, , 1-6.	1.1	2
9	Pattern of SQSTM1 Gene Variants in a Hungarian Cohort of Pagetâ€™s Disease of Bone. Calcified Tissue International, 2021, 108, 159-164.	3.1	2
10	Brain network reorganisation and spatial lesion distribution in systemic lupus erythematosus. Lupus, 2021, 30, 285-298.	1.6	6
11	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	3.6	132
12	Mind the gaps: therapistsâ€™ experiences of managing symptomatic hypermobility in Scotland. Rheumatology Advances in Practice, 2021, 5, rkab046.	0.7	1
13	A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatology International, 2021, 41, 921-928.	3.0	8
14	Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation. Calcified Tissue International, 2021, 109, 92-102.	3.1	7
15	Epigenetic analysis of Pagetâ€™s disease of bone identifies differentially methylated loci that predict disease status. ELife, 2021, 10, .	6.0	9
16	Ubiquitin-protein ligase Ubr5 cooperates with hedgehog signalling to promote skeletal tissue homeostasis. PLoS Genetics, 2021, 17, e1009275.	3.5	4
17	P112â€ƒTeriparatide versus anti-resorptive treatment in rheumatoid arthritis patients with severe osteoporosis: an observational study. Rheumatology, 2021, 60, .	1.9	0
18	Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance. Calcified Tissue International, 2021, 109, 351-362.	3.1	32

#	Article	IF	Citations
19	Genetic Determinants of Pagetâ€™s Disease of Bone. Current Osteoporosis Reports, 2021, 19, 327-337.	3.6	12
20	Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial. Circulation, 2021, 143, 2418-2427.	1.6	61
21	Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro. Calcified Tissue International, 2021, 109, 696-705.	3.1	5
22	Response by Bing et al to Letter Regarding Article, â€œEffect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trialâ€. Circulation, 2021, 144, e335.	1.6	0
23	Response to: Effects of Alendronic Acid on Fracture Healing. Journal of Bone and Mineral Research, 2020, 35, 215-216.	2.8	0
24	Lossâ€ofâ€Function Mutations in the ALPL Gene Presenting with Adult Onset Osteoporosis and Low Serum Concentrations of Total Alkaline Phosphatase. Journal of Bone and Mineral Research, 2020, 35, 657-661.	2.8	23
25	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1682-1699.	3.6	53
26	A New Gene for Susceptibility to Paget's Disease of Bone and for Multisystem Proteinopathy. Journal of Bone and Mineral Research, 2020, 35, 1385-1386.	2.8	4
27	Rheumatology in a time of Coronavirus: lessons from our early experiences. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 715-716.	0.5	1
28	Pagetâ€™s disease of bone: when and why to refer to specialist care. British Journal of General Practice, 2020, 70, 561-562.	1.4	2
29	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2020, 396, 1745-1757.	13.7	192
30	Bisphosphonates in the management of Paget's disease. Bone, 2020, 138, 115465.	2.9	17
31	Characteristics of Early Paget's Disease in <scp>SQSTM1</scp> Mutation Carriers: Baseline Analysis of the <scp>ZiPP</scp> Study Cohort. Journal of Bone and Mineral Research, 2020, 35, 1246-1252.	2.8	12
32	Adult hypophosphatasia with a novel ALPL mutation: Report of an Indian kindred. Bone Reports, 2020, 12, 100247.	0.4	3
33	Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020. Frontiers in Endocrinology, 2020, 11, 630875.	3.5	5
34	Insertion Mutation in Tnfrsf11a Causes a Paget's Diseaseâ€“Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice. Journal of Bone and Mineral Research, 2020, 36, 1376-1386.	2.8	10
35	Disentangling the genetics of lean mass. American Journal of Clinical Nutrition, 2019, 109, 276-287.	4.7	38
36	Clinical Guidelines on Paget's Disease of Bone. Journal of Bone and Mineral Research, 2019, 34, 2327-2329.	2.8	43

#	Article	IF	Citations
37	Liver-derived IGF-I is not required for protection against osteoarthritis in male mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1150-E1157.	3.5	3
38	Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 2019, 44, 452-466.	6.1	30
39	Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis. Calcified Tissue International, 2019, 105, 148-155.	3.1	11
40	Focal and Osteosclerotic Bone Diseases. Calcified Tissue International, 2019, 104, 481-482.	3.1	0
41	Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2019, 34, 1025-1032.	2.8	22
42	Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. Journal of Bone and Mineral Research, 2019, 34, 579-604.	2.8	102
43	Rare Inherited forms of Pagetâ€™s Disease and Related Syndromes. Calcified Tissue International, 2019, 104, 501-516.	3.1	26
44	Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis. Journal of Materials Science: Materials in Medicine, 2019, 30, 25.	3.6	6
45	Analysis of Transcriptional Regulation in Bone Cells. Methods in Molecular Biology, 2019, 1914, 145-167.	0.9	0
46	Zoledronate in the prevention of Pagetâ€™s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to preventSQSTM1-mediated Pagetâ€™s disease of bone. BMJ Open, 2019, 9, e030689.	1.9	15
47	Management of Osteogenesis Imperfecta. Frontiers in Endocrinology, 2019, 10, 924.	3.5	49
48	Osteoimmunology. Calcified Tissue International, 2018, 102, 501-502.	3.1	10
49	Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. American Journal of Human Genetics, 2018, 102, 88-102.	6.2	252
50	Cognitive function, disease burden and the structural connectome in systemic lupus erythematosus. Lupus, 2018, 27, 1329-1337.	1.6	14
51	Raman spectroscopy predicts the link between claw keratin and bone collagen structure in a rodent model of oestrogen deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 398-406.	3.8	26
52	Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. Annals of the Rheumatic Diseases, 2018, 77, 378-385.	0.9	21
53	Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	11
54	TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. Journal of Clinical Investigation, 2018, 128, 1164-1177.	8.2	75

#	Article	IF	Citations
55	Regulation of breast cancer induced bone disease by cancer-specific IKKÎ². Oncotarget, 2018, 9, 16134-16148.	1.8	6
56	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 2017, 38, ehw387.	2.2	58
57	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. JAMA Oncology, 2017, 3, 636.	7.1	376
58	Longâ€Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISMâ€EZ Study. Journal of Bone and Mineral Research, 2017, 32, 1165-1173.	2.8	50
59	Antibody Response to Paramyxoviruses in Pagetâ€™s Disease of Bone. Calcified Tissue International, 2017, 101, 141-147.	3.1	20
60	Raman spectral variation for human fingernails of postmenopausal women is dependent on fracture risk and osteoporosis status. Journal of Raman Spectroscopy, 2017, 48, 813-821.	2.5	11
61	The Reply. American Journal of Medicine, 2017, 130, e457.	1.5	0
62	Combined deficiency of the Cnr1 and Cnr2 receptors protects against ageâ€related bone loss by osteoclast inhibition. Aging Cell, 2017, 16, 1051-1061.	6.7	39
63	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nature Communications, 2017, 8, 80.	12.8	147
64	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 2017, 105, 11-17.	2.9	373
65	How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders. Journal of Bone and Mineral Research, 2017, 32, 2324-2330.	2.8	1
66	Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcified Tissue International, 2017, 101, 375-383.	3.1	25
67	High mortality in younger patients with major osteoporotic fractures. Osteoporosis International, 2017, 28, 1047-1052.	3.1	9
68	Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus, 2017, 26, 588-597.	1.6	29
69	Heavy Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of Fractures. American Journal of Medicine, 2017, 130, 214-221.	1.5	56
70	200â€ƒAutoantibodies to Osteoprotegerin and Bone Mineral Density in Axial Spondyloarthritis. Rheumatology, 2016, , .	1.9	0
71	Biology and Treatment of Paget's Disease of Bone. Journal of Cellular Biochemistry, 2016, 117, 289-299.	2.6	49
72	Cerebral Small Vessel Disease Burden Is Increased in Systemic Lupus Erythematosus. Stroke, 2016, 47, 2722-2728.	2.0	50

#	Article	IF	Citations
73	Novel Genetic Variants Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of SLC1A3 and EPHB2. Journal of Bone and Mineral Research, 2016, 31, 2085-2097.	2.8	42
74	Raman Spectroscopic Analysis of Fingernail Clippings Can Help Differentiate between Postmenopausal Women who Have and Have Not Suffered a Fracture. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2016, 9, CMAMD.S38493.	1.2	10
75	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 2016, 17, 461.	1.9	22
76	New Targets and New Treatments: Recent Advances in the Treatment of Musculoskeletal Disease. Calcified Tissue International, 2016, 98, 317-318.	3.1	1
77	Cerebrovascular Disease in Rheumatic Diseases. Stroke, 2016, 47, 943-950.	2.0	117
78	Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-Î²B and Interferon Signaling: Implications for Pagetâ€™s Disease. Cell Reports, 2015, 13, 1096-1102.	6.4	61
79	Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. Journal of Biological Chemistry, 2015, 290, 22049-22060.	3.4	33
80	Targeted sequencing of the Paget's disease associated 14q32 locus identifies several missense coding variants in RIN3 that predispose to Paget's disease of bone. Human Molecular Genetics, 2015, 24, 3286-3295.	2.9	29
81	Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1631-1632.	0.9	16
82	Wholeâ€genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature, 2015, 526, 112-117.	27.8	483
83	Predictors of poor clinical outcome following hip fracture in middle aged-patients. Injury, 2015, 46, 709-712.	1.7	9
84	Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice. Annals of the Rheumatic Diseases, 2015, 74, 220-226.	0.9	14
85	Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence Based. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L45-L46.	3.6	5
86	Clinical Presentation of Pagetâ€™s Disease: Evaluation of a Contemporary Cohort and Systematic Review. Calcified Tissue International, 2014, 95, 385-392.	3.1	89
87	A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. Annals of the Rheumatic Diseases, 2014, 73, 2130-2136.	0.9	108
88	Paget's disease of bone. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 865-869.	0.5	21
89	Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover. Calcified Tissue International, 2014, 94, 259-268.	3.1	21
90	Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology, 2014, 53, 1759-1766.	1.9	119

#	Article	IF	Citations
91	Genetics of Pagetâ€™s Disease of Bone. Current Osteoporosis Reports, 2014, 12, 263-271.	3.6	37
92	The Influence of Vitamin C on the Outcome of Distal Radial Fractures. Journal of Bone and Joint Surgery - Series A, 2014, 96, 1451-1459.	3.0	72
93	Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 2014, 44, 25-30.	3.4	42
94	Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 992-1000.	3.8	28
95	Apolipoprotein E isoforms and boneâ€"of mice and men. Journal of Bone and Mineral Research, 2013, 28, 234-235.	2.8	2
96	Paget's Disease of Bone. New England Journal of Medicine, 2013, 368, 644-650.	27.0	146
97	Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease. Journal of Bone and Mineral Research, 2013, 28, 2338-2346.	2.8	50
98	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	21.4	1,100
99	Pathogenesis of Paget Disease of Bone. Calcified Tissue International, 2012, 91, 97-113.	3.1	123
100	Hydrogen sulphideâ€releasing diclofenac derivatives inhibit breast cancerâ€induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. British Journal of Pharmacology, 2012, 165, 1914-1925.	5.4	34
101	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nature Genetics, 2011, 43, 685-689.	21.4	158
102	Genetic determinants of Paget's disease of bone. Annals of the New York Academy of Sciences, 2011, 1240, 53-60.	3.8	25
103	Randomized Trial of Alendronate Plus Vitamin D3 Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency. Calcified Tissue International, 2011, 88, 485-494.	3.1	27
104	Signal peptide mutations in RANK prevent downstream activation of NF-ÎºB. Journal of Bone and Mineral Research, 2011, 26, 1926-1938.	2.8	27
105	The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation. Endocrinology, 2011, 152, 2141-2149.	2.8	92
106	A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Human Molecular Genetics, 2011, 20, 2734-2744.	2.9	114
107	Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone. Journal of Bone and Mineral Research, 2010, 25, 20-31.	2.8	147
108	Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate. Calcified Tissue International, 2010, 87, 298-304.	3.1	13

#	Article	IF	Citations
109	Osteoporosis as an Hereditary Disease. Clinical Reviews in Bone and Mineral Metabolism, 2010, 8, 68-76.	0.8	14
110	Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. Journal of Bone and Mineral Research, 2010, 25, 2368-2373.	2.8	77
111	Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone. Journal of Bone and Mineral Research, 2010, 25, 2592-2605.	2.8	42
112	Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nature Genetics, 2010, 42, 520-524.	21.4	258
113	Genetics of osteoporosis. Annals of the New York Academy of Sciences, 2010, 1192, 181-189.	3.8	75
114	Genetics of Osteoporosis. Endocrine Reviews, 2010, 31, 629-662.	20.1	316
115	Patient-Reported Outcomes in Rheumatoid Arthritis. Patient, 2010, 3, 133-143.	2.7	8
116	Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 2009, 10, 139-147.	16.2	151
117	Identification of a Major Locus for Paget's Disease on Chromosome 10p13 in Families of British Descent. Journal of Bone and Mineral Research, 2008, 23, 58-63.	2.8	47
118	Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro. Calcified Tissue International, 2008, 82, 191-201.	3.1	187
119	Clinical and Biochemical Response of TNFRSF11A-Mediated Early-Onset Familial Paget Disease to Bisphosphonate Therapy. Calcified Tissue International, 2008, 83, 272-275.	3.1	10
120	Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders. Best Practice and Research in Clinical Rheumatology, 2008, 22, 101-111.	3.3	36
121	Pathogenesis of Paget's disease of bone. Bone, 2008, 43, 819-825.	2.9	95
122	Pathogenesis and management of Paget's disease of bone. Lancet, The, 2008, 372, 155-163.	13.7	227
123	Meta-Analysis of Genome-Wide Scans Provides Evidence for Sex- and Site-Specific Regulation of Bone Mass. Journal of Bone and Mineral Research, 2007, 22, 173-183.	2.8	144
124	Genetics of osteoporosis. Proceedings of the Nutrition Society, 2007, 66, 158-165.	1.0	70
125	Multicenter Blinded Analysis of RT-PCR Detection Methods for Paramyxoviruses in Relation to Paget's Disease of Bone. Journal of Bone and Mineral Research, 2007, 22, 569-577.	2.8	65
126	Identification of Sex-Specific Associations Between Polymorphisms of the Osteoprotegerin Gene, TNFRSF11B, and Paget's Disease of Bone. Journal of Bone and Mineral Research, 2007, 22, 1062-1071.	2.8	59

#	Article	IF	Citations
127	Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study. PLoS Medicine, 2006, 3, e90.	8.4	160
128	p62 mutations, ubiquitin recognition and Paget's disease of bone. Biochemical Society Transactions, 2006, 34, 735-737.	3.4	25
129	Genetic regulation of bone mass and susceptibility to osteoporosis. Genes and Development, 2006, 20, 2492-2506.	5.9	275
130	Genetic determinants of osteoporosis. Current Opinion in Rheumatology, 2005, 17, 475-479.	4.3	70
131	Association of COLIA1 Sp1 Alleles with Defective Bone Nodule Formation In Vitro and Abnormal Bone Mineralization In Vivo. Calcified Tissue International, 2005, 77, 113-118.	3.1	57
132	Loci for regulation of bone mineral density in men and women identified by genome wide linkage scan: the FAMOS study. Human Molecular Genetics, 2005, 14, 943-951.	2.9	124
133	Susceptibility to Paget's Disease of Bone Is Influenced by a Common Polymorphic Variant of Osteoprotegerin. Journal of Bone and Mineral Research, 2004, 19, 1506-1511.	2.8	59
134	Loss of Ubiquitin-Binding Associated With Paget's Disease of Bone p62 (SQSTM1) Mutations. Journal of Bone and Mineral Research, 2004, 20, 619-624.	2.8	97
135	Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget's disease of bone. Biochemical Society Transactions, 2004, 32, 728-730.	3.4	32
136	Phenotypic Characterization of Early Onset Paget's Disease of Bone Caused by a 27-bp Duplication in the TNFRSF11A Gene. Journal of Bone and Mineral Research, 2003, 18, 1381-1385.	2.8	109
137	Medical Management of Hypercalcemia. Calcified Tissue International, 2003, 74, 1-11.	3.1	23
138	Genetic determinants of susceptibility to osteoporosis. Current Opinion in Pharmacology, 2003, 3, 286-290.	3.5	38
139	Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Human Molecular Genetics, 2002, 11, 2735-2739.	2.9	307
140	Guidelines on the management of Pagetâ€™s disease of bone*. Bone, 2002, 31, 366-373.	2.9	205
141	The Effect of Nutrient Intake on Bone Mineral Status in Young Adults: The Northern Ireland Young Hearts Project. Calcified Tissue International, 2002, 70, 89-98.	3.1	43
142	COLIA1 Sp1 Polymorphism Predicts Response of Femoral Neck Bone Density to Cyclical Etidronate Therapy. Calcified Tissue International, 2002, 70, 158-163.	3.1	65
143	The Pro and Con of Measles Virus in Paget's Disease: Con. Journal of Bone and Mineral Research, 2002, 17, 2290-2292.	2.8	40
144	Pathogenesis of Paget's Disease of Bone. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 109-114.	0.8	7

#	Article	IF	Citations
145	Genomewide Search in Familial Paget Disease of Bone Shows Evidence of Genetic Heterogeneity with Candidate Loci on Chromosomes 2q36, 10p13, and 5q35. American Journal of Human Genetics, 2001, 69, 1055-1061.	6.2	113
146	The synthesis and evaluation of o-phenylenediamine derivatives as fluorescent probes for nitric oxide detection. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 2553-2559.	1.3	39
147	Mutation Screening of the TNFRSF11A Gene Encoding Receptor Activator of NFkB (RANK) in Familial and Sporadic Paget's Disease of Bone and Osteosarcoma. Calcified Tissue International, 2001, 68, 151-155.	3.1	75
148	Studies of Bone Density, Quantitative Ultrasound, and Vertebral Fractures in Relation to Collagen Type I Alpha 1 Alleles in Elderly Women. Calcified Tissue International, 2001, 68, 348-351.	3.1	36
149	Role of genetic factors in the pathophysiology and management of osteoporosis. Clinical Endocrinology, 2001, 54, 1-9.	2.4	31
150	Nitric oxide and bone. Immunology, 2001, 103, 255-261.	4.4	444
151	COL1A1 Sp1 Polymorphism Predicts Perimenopausal and Early Postmenopausal Spinal Bone Loss. Journal of Bone and Mineral Research, 2001, 16, 1634-1641.	2.8	66
152	Genetics of osteoporosis. , 2001, 2, 13-21.		10
153	Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genetics, 2000, 24, 45-48.	21.4	457
154	A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation. Oncogene, 2000, 19, 4437-4440.	5.9	133
155	A Negative Search for a Paramyxoviral Etiology of Paget's Disease of Bone: Molecular, Immunological, and Ultrastructural Studies in U.K. Patients. Journal of Bone and Mineral Research, 2000, 15, 2315-2329.	2.8	132
156	Paget's Disease of Bone: Evidence for a Susceptibility Locus on Chromosome 18q and for Genetic Heterogeneity. Journal of Bone and Mineral Research, 1998, 13, 911-917.	2.8	125
157	An Sp1 Binding Site Polymorphism in the COLIA1 Gene Predicts Osteoporotic Fractures in Both Men and Women. Journal of Bone and Mineral Research, 1998, 13, 1384-1389.	2.8	156
158	Do genetic markers aid in risk assessment?. Osteoporosis International, 1998, 8 Suppl 1, S37-42.	3.1	18
159	The genetics of osteoporosis. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 247-251.	0.5	64
160	The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas!. Rheumatology, 1997, 36, 831-838.	1.9	88
161	The effect of hyperoxia on the expression of cytokine mRNA in endothelial cells. Biochemical Society Transactions, 1997, 25, 292S-292S.	3.4	16
162	Genetic markers of bone metabolism and bone disease. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 114-121.	1.2	5

#	Article	IF	Citations
163	Expression of Nitric Oxide Synthase Isoforms in Bone and Bone Cell Cultures. Journal of Bone and Mineral Research, 1997, 12, 1108-1115.	2.8	148
164	Genetic markers of bone metabolism and bone disease. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement, 1997, 227, 114-21.	2.7	3
165	Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I Î± 1 gene. Nature Genetics, 1996, 14, 203-205.	21.4	639
166	Nitric oxide and bone. Journal of Bone and Mineral Research, 1996, 11, 300-305.	2.8	158
167	Pharmacological Management of Back Pain Syndromes. Drugs, 1994, 48, 189-198.	10.9	24
168	Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bon. Journal of Bone and Mineral Research, 1994, 9, 11-16.	2.8	77
169	Pathogenesis and management of cancer associated hypercalcaemia. Cancer Surveys, 1994, 21, 179-96.	1.5	23
170	Clinical experience with pamidronate in the treatment of Paget's disease of bone.. Annals of the Rheumatic Diseases, 1991, 50, 930-933.	0.9	36
171	Failure to detect paramyxovirus sequences in paget's disease of bone using the polymerase chain reaction. Journal of Bone and Mineral Research, 1991, 6, 1243-1248.	2.8	81
172	SIDE-EFFECTS OF PAMIDRONATE. Lancet, The, 1989, 334, 42-43.	13.7	74
173	The effect of 1Î±-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated paget's disease â€" a double-blind randomized clinical study. Journal of Bone and Mineral Research, 1987, 2, 5-12.	2.8	32
174	Epigenetic DNA Methylation Signatures Associated With the Severity of Pagetâ€™s Disease of Bone. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	3